|
Synonyms: campath 1H | Campath® | campath-1H | Lemtrada®
alemtuzumab is an approved drug (FDA (2001), EMA (2013))
Compound class:
Antibody
Comment: CAMPATH-1 (CD52) antigen inhibitor. Functionally, alemtuzumab causes depletion and then recovery of the immune system.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. 
View more information in the IUPHAR Pharmacology Education Project: alemtuzumab |
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes (FDA (2001), EMA (2013)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 8005 | alemtuzumab |
| Synonyms |
| campath 1H | Campath® | campath-1H | Lemtrada® |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 11 |
| Other databases | |
| GtoPdb PubChem SID | 178103376 |
| PubChem SID | 178103376 |
| Search PubMed clinical trials | alemtuzumab |
| Search PubMed titles | alemtuzumab |
| Search PubMed titles/abstracts | alemtuzumab |
| Wikipedia | Alemtuzumab |
